RESUMO
Cholangiocarcinoma is a biliary tree cancer of unknown etiology, whose symptoms are unspecific and is usually detected in advanced stages. Surgery continues to be the only curative therapy. Median survival in patients with inoperable tumors ranges between 5 and 8 months. There are few studies on the effects of chemotherapy, with a very small response. We report four patients with advanced cholangiocarcinoma, treated with gemcitabine 1000 mg/m2, weekly for 3 weeks every 28 days. There was a stabilization of tumor size and symptoms were alleviated. Toxicity was low and there was a probable prolongation of survival
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias dos Ductos Biliares , Colangiocarcinoma , Desoxicitidina , Antineoplásicos/farmacologia , Qualidade de Vida , Leucovorina , Taxa de Sobrevida , Resultado do Tratamento , Desoxicitidina , Quimioterapia Combinada , Fluoruracila , Lomustina , Antineoplásicos/administração & dosagem , Ductos Biliares Intra-HepáticosRESUMO
Existe una amplia gama de drogas de quimioterapia que son activas en cáncer de mama, estas son útiles en adyuvancia, inducción y tratamiento de enfermedad diseminada. La quimioterapia adyuvante se aplica a paientes que tenían enfermedad localizada en mama con o sin ganglios comprometidos. en que se ha resecado toda la enfermedad con el objetivo de prevenir el crecimiento de células neoplásicas latentes en el sitio primario de la enfermedad o a distancia. La indicación terapéutica debe hacerse de acuerdo a una evaluación de múltiples factores. La quimioterapia neoadyuvante ha permitido cambiar el panorama pronóstico del cáncer de mama localmente avanzado, permitiendo la iniciación precoz de una terapia sistématica; disminuyendo la extensión de los bordes de la resección quirúrgica permitiendo identificar la respuesta a la terapia "in vivo". Con la quimioterapia neoadyuvante, cerca del 80 por ciento de las pacientes logran una reducción superior al 50 por ciento del volumen de la enfermedad mamaria y axilar. El objetivo principal del tratamiento del cáncer de mama matastásico es pailar los síntomas de la enfermedad y prolongar la sobrevida, y aunque la enfermedad no es curable con tratamiento convencional, un porcentaje de enfermas (2 a 10 por ciento) puede obtener remisiones completas mantenidas en el tiempo
Assuntos
Humanos , Feminino , Neoplasias da Mama , Quimioterapia Adjuvante , Antineoplásicos/farmacologia , Neoplasias da Mama , Intervalo Livre de Doença , Quimioterapia Combinada , Pós-Menopausa , Prognóstico , Qualidade de Vida , RecidivaRESUMO
Surgery continues to be the only curative therapy for gallbladder cancer, but useful in very few patients. Mean survival of patients with gallbladder cancer, that are out of the reach of surgery, is 3 months. The few clinical trials of chemotherapy for this disease, report very low success rates. We report four patients with advanced gallbladder cancer, treated with gemcitabine in an intravenous dose of 1000 mg/m2, given in 30 min, once a week during three consecutive weeks, every 28 days. There was a partial response that lasted 40,3 23,2 weeks with a mean survival of 59,75 17 weeks. One patient survives without evidences of disease after 17 months of the diagnosis of an advanced cancer. In all patients, symptoms were alleviated, functional status and quality of life improved. Toxicity was mild and did not require reduction in doses or delay in therapy. Therefore, this medication deserves further investigation for the treatment of gallbladder cancer